Profile data is unavailable for this security.
About the company
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
- Revenue in GBP (TTM)42.71bn
- Net income in GBP6.91bn
- Incorporated1992
- Employees94.30k
- LocationAstraZeneca PLC1 Francis Crick AvenueCambridge Biomedical CampusCAMBRIDGE CB2 0AAUnited KingdomGBR
- Phone+44 203 749 5000
- Fax+44 207 604 8151
- Websitehttps://www.astrazeneca.com/
Mergers & acquisitions
| Acquired company | AZN:LSE since announced | Transaction value |
|---|---|---|
| SixPeaks Bio AG | 13.07% | 300.00m |
| Esobiotec Srl | 17.59% | 1.00bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | 45.97bn | 5.69bn | 113.68bn | 81.00k | 20.09 | -- | 11.12 | 2.47 | 1.36 | 1.36 | 10.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 75.81 | 69.03 | 12.44 | 19.52 | -- | 9.38 | -- | -- | -1.65 | 8.48 | -3.42 | 3.16 | -- | 2.50 |
| Novo Nordisk A/S | 35.91bn | 11.90bn | 116.39bn | 68.79k | 12.83 | 6.77 | 8.08 | 3.24 | 23.03 | 23.03 | 69.49 | 43.66 | 0.6128 | 1.30 | 4.33 | 4,492,601.00 | 20.31 | 25.03 | 35.60 | 48.23 | 80.98 | 83.95 | 33.14 | 33.96 | 0.5696 | -- | 0.4029 | 50.28 | 6.43 | 19.48 | 1.43 | 19.44 | 32.48 | 20.79 |
| Gilead Sciences Inc | 21.37bn | 5.96bn | 138.98bn | 17.60k | 23.70 | 8.79 | 17.40 | 6.50 | 6.43 | 6.43 | 23.05 | 17.34 | 0.5146 | 3.39 | 6.01 | 1,652,671.00 | 14.35 | 5.26 | 18.18 | 6.38 | 78.72 | 78.47 | 27.88 | 12.54 | 1.31 | 18.69 | 0.5376 | 108.47 | 6.04 | 5.08 | -91.53 | -38.34 | -8.71 | 4.10 |
| Amgen Inc | 27.00bn | 5.66bn | 152.02bn | 28.00k | 27.00 | 23.93 | 19.78 | 5.63 | 14.23 | 14.23 | 67.84 | 16.06 | 0.4029 | 1.48 | 4.49 | -- | 8.45 | 7.90 | 11.52 | 10.18 | 73.30 | 74.68 | 20.98 | 20.55 | 0.8958 | 18.59 | 0.8631 | 72.99 | 9.95 | 7.65 | 88.53 | 1.20 | 25.03 | 8.27 |
| AstraZeneca plc | 42.71bn | 6.91bn | 217.40bn | 94.30k | 31.69 | 6.45 | 19.90 | 5.09 | 4.42 | 4.42 | 27.35 | 21.74 | 0.5299 | 1.72 | 4.43 | 452,940.60 | 8.57 | 4.32 | 11.81 | 5.95 | 81.90 | 80.22 | 16.18 | 9.39 | 0.6856 | 10.39 | 0.4152 | 107.68 | 18.03 | 17.27 | 18.14 | 39.43 | 13.27 | 1.20 |
| Merck & Co Inc | 47.75bn | 13.41bn | 222.30bn | 75.00k | 16.76 | -- | 16.19 | 4.66 | 7.28 | 7.28 | 25.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 78.55 | 75.41 | 28.09 | 21.08 | -- | 22.68 | -- | -- | 1.31 | 9.38 | 6.64 | 32.21 | -- | 6.01 |
| Novartis | 41.38bn | 10.27bn | 239.24bn | 75.88k | 21.54 | 6.41 | 17.41 | 5.78 | 5.55 | 5.55 | 22.38 | 18.65 | 0.5284 | 2.27 | 6.89 | -- | 13.10 | 11.11 | 17.82 | 14.89 | 75.82 | 74.78 | 24.79 | 26.20 | 0.8868 | 16.89 | 0.4318 | 62.30 | 8.91 | 2.45 | 17.11 | 11.62 | 8.57 | 6.62 |
| Roche Holding AG | 58.25bn | 12.20bn | 273.95bn | 112.77k | 22.22 | 8.39 | 16.84 | 4.70 | 16.04 | 16.04 | 76.61 | 42.49 | 0.6076 | 2.15 | 5.40 | 545,480.30 | 13.63 | 13.69 | 19.85 | 21.13 | 73.62 | 72.22 | 22.43 | 20.80 | 1.12 | 16.42 | 0.4551 | 65.69 | 1.69 | 1.07 | 55.61 | -2.06 | 3.50 | 1.49 |
| AbbVie Inc | 43.81bn | 1.72bn | 290.07bn | 55.00k | 168.59 | -- | 36.70 | 6.62 | 1.33 | 1.33 | 33.68 | -1.49 | 0.4302 | 3.66 | 4.92 | 1,084,436.00 | 1.73 | 5.44 | 2.46 | 7.09 | 71.16 | 68.89 | 4.02 | 13.73 | 0.5992 | 7.60 | 1.04 | 134.96 | 3.71 | 11.11 | -12.07 | -11.58 | 12.03 | 8.00 |
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Dec 2024 | 65.12m | 4.20% |
| BlackRock Investment Management (UK) Ltd.as of 31 Mar 2025 | 55.81m | 3.60% |
| Capital Research & Management Co. (World Investors)as of 02 Dec 2025 | 52.90m | 3.41% |
| The Vanguard Group, Inc.as of 02 Jan 2026 | 41.00m | 2.64% |
| Norges Bank Investment Managementas of 02 Jan 2026 | 32.33m | 2.09% |
| BlackRock Fund Advisorsas of 02 Jan 2026 | 19.23m | 1.24% |
| Vanguard Asset Management Ltd.as of 31 Dec 2025 | 17.96m | 1.16% |
| Goldman Sachs Asset Management LPas of 02 Jan 2026 | 17.25m | 1.11% |
| SSgA Funds Management, Inc.as of 02 Jan 2026 | 16.93m | 1.09% |
| Legal & General Investment Management Ltd.as of 02 Jan 2026 | 16.74m | 1.08% |
